NCT00074412View on ClinicalTrials.gov

Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding

PHASE3CompletedINTERVENTIONAL
Enrollment

2,026

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

November 30, 2011

Conditions
HIV Infections
Interventions
DRUG

Nevirapine

10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.

DRUG

Nevirapine placebo

Oral suspension taken once daily up to 6 months of age

Trial Locations (5)

Unknown

CAPRISA Umlazi CRS, Umlazi

Muhimbili University of Health and Allied Sciences (MUHAS) CRS, Dar es Salaam

Makerere University- JHU Research Collaboration {MUJHU CARE LTD} CRS, Kampala

Seke North CRS, Chitungwiza

St Mary's CRS, Chitungwiza

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

NCT00074412 - Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding | Biotech Hunter | Biotech Hunter